Neuroblastoma in adolescents

Cancer

Volumn 98, Issue 2, 2003, Pages 349-355

  Gaspar, Nathalie ^a   Hartmann, Olivier ^a   Munzer, Caroline ^b   Bergeron, Christophe ^c   Millot, Frédéric ^d   Cousin Lafay, Lucie ^e   Babin Boilletot, Annie ^f   Blouin, Pascale ^g   Pajot, Christine ^b   Coze, Carole ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL DES ENFANTS   (France)

^c CENTRE LÉON BÉRARD   (France)

^d University of Poitiers   (France)

^e Institut de Recherche sur le Cancer de Lille   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g HÔPITAL PELLEGRIN   (France)

^h TIMONE HOSPITAL   (France)

Author keywords

Adolescent; Indolent course; Neuroblastoma; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CATECHOLAMINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CATECHOLAMINE URINE LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NEUROBLASTOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TREATMENT OUTCOME; URINALYSIS;

ABDOMINAL NEOPLASMS; ADOLESCENT; CASE-CONTROL STUDIES; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0037669553     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11521     Document Type: Article

References (19)

1. Hartmann O, Scopinaro M, Tournade MF, et al. Neuroblastomas treated at the Gustave-Roussy Institute from 1975 to 1979. 173 cases. Arch Fr Pediatr. 1983;40:15-21.
2. Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 1997;15:1171-1182.
3. Finklestein JZ, Klemperer MR, Evans A, et al. Multiagent chemotherapy for children with metastatic neuroblastoma: a report from the Children's Cancer Study Group. Med Pediatr Oncol. 1979;6:179-188.
4. Blatt J, Gula MJ, Orlando SJ, et al. Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis. Cancer. 1995;76:890-894.
5. Franks LM, Bollen A, Seeger RC, et al. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer. 1997;79:2028-2035.
6. Laprie A, Coze C, Valteau-Couanet D, et al. Localized neuroblastoma and Myc-N amplification: improved survival with high-dose chemotherapy and locoregional irradiation. Oral communication no. 13. Advances in Neuroblastoma Research; June 17-19, 2002; Paris, France. Toulouse, France: SFOP, 2002.
7. Coze C, Hartmann O, Michon J, et al. NB87 induction protocol for Stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol. 1997;15:3433-3440.
8. Frappaz D, Bonneu A, Chauvot P, et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol. 2000;34:237-241.
9. Valteau-Couanet D, Michon J, Perel Y, et al. Results of NB97 SFOP Protocol in Children over 1 year with Stage 4 neuroblastoma. Med Pediatr Oncol. 2002;39:371.
10. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
11. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's Cancer Study Group A. Cancer. 1971;27:374-378.
12. Ladenstein R, Lasset C, Hartmann O, et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1994;14:37-46.
13. Hartmann O, Valteau-Couanet D, Benhamou E, et al. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer. 1997;33:2126-2129.
14. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in Stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol. 1998;16: 953-965.
15. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant. 1999;23:789-795.
16. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
17. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954-1961.
18. Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol. 1996;14:25-34.
19. Bénard JHO, Terrier-Lacombe MJ, Bayle C, Lemerle J, Riou G. Génes impliqués danq la dissémination métastatique et la réponse à la chimiothérapie du neuroblastome. Médecine/Sciences. 1996;12:756-765.